Uncategorized - August 15, 2014
British healthcare institute presents Airsonett evaluation
NICE, the National Institute for Health and Care Excellence, has performed a review of available scientific data and compiled factual basis to facilitate decisions regarding the use of the asthma treatment Airsonett within British healthcare. NICE has done a so called Medtech Innovation Briefing where the institute notes that Airsonett could improve the life quality […]
Clinical Trials - August 15, 2014
Active Biotech’s partner Teva starts laquinimod clinical trial
Active Biotech has announced that its partner Teva Pharmaceutical Industries Ltd. will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease. Teva started a global research collaboration in the summer of 2013 to develop laquinimod as a treatment for Huntington’s disease. Earlier this year, […]
Uncategorized - August 14, 2014
New method to show cancer genes in microscope
Researchers at Uppsala University have developed a new method to visualize gene damages that cause cancer. The method can be used to understand the development of cancer and improve future cancer diagnostics. The results of the study have been presented online in the Journal of Pathology. Gene mutations are the cause of cancer development. There […]
Clinical Trials - August 14, 2014
AstraZeneca starts phase III program for asthma treatment
AstraZeneca has announced the start of the Phase III programme for tralokinumab, developed by MedImmune. Tralokinumab is a potential treatment for patients with severe, inadequately controlled asthma. The Phase III program will evaluate the safety and effectiveness of tralokinumab in reducing the rate of asthma exacerbations (AER) in adults and adolescents with severe, inadequately controlled asthma despite receiving […]
Pharma Business - August 14, 2014
Novozymes presents half year results
Danish Novozymes presents a first-half performance in line with expectations, a full-year profit outlook increased. Sales growth in the first half was in line with expectations, within the range for full-year outlook, according to the company. Organically, sales grew by 8% (4% DKK, 8% LCY). Sales growth slowed down during the period as expected after […]
MedTech Business - August 13, 2014
Xvivo gets FDA approval for lung perfusion system
The company has received approval from the FDA for the products XPS and STEEN Solution for sale on the American market. The approval, which is the first in the USA for warm perfusion of organs outside the body pending transplantation, means that STEEN Solution, XPS and the accompanying single-use articles are the only medical device […]
